Research ExplorerScientific StaffRichard Tilman Hauch Publications

Richard Tilman Hauch

graph of relations
Affiliations
1 - 7 out of 7Page size: 50

Publications

  1. Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis

    Dill, V., Kauschinger, J., Hauch, R. T., Buschhorn, L., Odinius, T. O., Müller-Thomas, C., Mishra, R., Kyncl, M. C., Schmidt, B., Prodinger, P. M., Hempel, D., Bellos, F., Höllein, A., Kern, W., Haferlach, T., Slotta-Huspenina, J., Bassermann, F., Peschel, C., Götze, K. S., Waizenegger, I. C., Höckendorf, U., Jost, P. J. & Jilg, S., 22.11.2019, In: EUR J HAEMATOL. 104, 2, p. 125-137 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  2. Elevated RIPK3 correlates with disease burden in myelofibrosis

    Dill, V., Wagner, C. V., Keller, E. C., Fernandez-Hernandez, F. J., Shoumariyeh, K., Odinius, T. O., Buschhorn, L., Hauch, R. T., Suren, C., Hecker, J. S., Herhaus, P., Sandherr, M., Schmidt, B., Slotta-Huspenina, J., Bassermann, F., Höckendorf, U., Jilg, S., Branca, C., Vosberg, S. & Jost, P. J., 11.04.2023, In: BLOOD ADV. 7, 7, p. 1219-1224 6 p.

    Research output: SCORING: Contribution to journal › Letter › Research

  3. Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT: A Monocentric, Retrospective Study

    Hauch, R., Hinrichs, M., Ruhwald, R., Schrum, J., Rutkowski, S., Woessmann, W. & Winkler, B., 05.2023, In: KLIN PADIATR. 235, 3, p. 159-166 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  4. Correction: Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT

    Hauch, R., Hinrichs, M., Ruhwald, R., Schrum, J., Rutkowski, S., Woessmann, W. & Winkler, B., 05.2023, In: KLIN PADIATR. 235, 3, p. e1-e2

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  5. Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose

    Jilg, S., Hauch, R. T., Kauschinger, J., Buschhorn, L., Odinius, T. O., Dill, V., Müller-Thomas, C., Herold, T., Prodinger, P. M., Schmidt, B., Hempel, D., Bassermann, F., Peschel, C., Götze, K. S., Höckendorf, U., Haferlach, T. & Jost, P. J., 16.04.2019, In: EXP HEMATOL ONCOL. 8, p. 9

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  6. Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies

    Odinius, T. O., Buschhorn, L., Wagner, C., Hauch, R. T., Dill, V., Dechant, M., Buck, M. C., Shoumariyeh, K., Moog, P., Schwaab, J., Reiter, A., Brockow, K., Götze, K., Bassermann, F., Höckendorf, U., Branca, C., Jost, P. J. & Jilg, S., 02.2022, In: J CANCER RES CLIN. 148, 2, p. 331-340 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile

    Reidel, V., Kauschinger, J., Hauch, R. T., Müller-Thomas, C., Nadarajah, N., Burgkart, R., Schmidt, B., Hempel, D., Jacob, A., Slotta-Huspenina, J., Höckendorf, U., Peschel, C., Kern, W., Haferlach, T., Götze, K. S., Jilg, S. & Jost, P. J., 03.04.2019, In: ONCOTARGET. 9, 25, p. 17270-17281 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review